TRVI Trevi Therapeutics

Trevi Therapeutics Announces the Hiring of Key Talent

Trevi Therapeutics Announces the Hiring of Key Talent
EN
13/10/2020

Underlying

TRVITrevi Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trevi Therapeutics

Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTWO Take-Two Intera...
SXT Sensient Techno... ... (+39)

InsiderInsights Weekly Tables: April 16, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SXT SENSIENT TECHNOLOGIES CORPORATION
PRTY PARTY CITY HOLDCO INC.
HMTV HEMISPHERE MEDIA GROUP
QRHC QUEST RESOURCE HOLDING
MLI MUELLER INDUSTRIES INC.
PMD PSYCHEMEDICS CORP.
OCX ONCOCYTE
CDZI CADIZ INC.
MRSN MERSANA THERAPEUTICS
CNNE CANNAE HOLDINGS
QNTO QUAINT OAK BANCORP INC.
MMD MAINSTAY DEFINEDTERM MUNICIPAL HIGH INCOME FUND
STIM STIMSONITE CORP
TRVI TREVI THERAPEUTICS
PNTG PENNANT GROUP
PINE ALPINE INCOME PROPERTY TRUST
BDTX BLACK DIAMOND THERAPEUTICS
LYRA INC.
TARA LYRA THERAPEUTICS
IHRT INC.
CCCC PROTEON THERAPEUTICS INC
GRPN IHEARTMEDIA INC. CLASS A
BDSX C4 THERAPEUTICS
JAKK GROUPON INC.
INDT BIODESIX
CRCT JAKKS PACIFIC INC.
AEI INDUS REALTY TRUST INC
GRPH CRICUT
ATAI INC.
FORA ALSET EHOME INTERNATIONAL INC
NYC GRAPHITE BIO
YOU INC.
MYPS ATAI LIFE SCIENCES BV
ABIO FORIAN INC
NEW YORK CITY REIT INC
CLEAR SECURE INC
PLAYSTUDIOS INC
ARCA BIOPHARMA INC
04/16/22 April 16, 2022 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
SXT Sensient Techno...
MLI Mueller Industr... ... (+12)

InsiderInsights Daily Ratings Report: April 13, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

SXT SENSIENT TECHNOLOGIES CORPORATION
MLI MUELLER INDUSTRIES INC.
MRSN MERSANA THERAPEUTICS
STIM STIMSONITE CORP
TRVI TREVI THERAPEUTICS
PINE ALPINE INCOME PROPERTY TRUST
JAKK JAKKS PACIFIC INC.
GRPH GRAPHITE BIO
FORA INC.
NYC FORIAN INC
YOU NEW YORK CITY REIT INC
CLEAR SECURE INC
04/14/22 April 14, 2022 1 EN
 PRESS RELEASE
Free
TRVI Trevi Therapeut...

Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcar...

Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference NEW HAVEN, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host investor meetings, at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021. Trevi’s presentation is scheduled for 2:15 p.m. ET. A li...

April 7, 2021 1 EN
 PRESS RELEASE
Free
TRVI Trevi Therapeut...

Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financia...

Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022 NEW HAVEN, Conn., March 25, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial resu...

March 25, 2021 1 EN
 PRESS RELEASE
Free
TRVI Trevi Therapeut...

Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on...

Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25 Conference Call and Webcast to be Held at 4:30 p.m. ET NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on March 25, 2021, to provide a corporate update and review the Company’s financial results ...

March 18, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch